GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Buyback Yield %

Swedish Orphan Biovitrum AB (OSTO:SOBI) Buyback Yield % : -0.18 (As of May. 01, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Swedish Orphan Biovitrum AB's current buyback yield was -0.18%.


Swedish Orphan Biovitrum AB Buyback Yield % Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Buyback Yield % Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.14 -6.76 -0.39

Swedish Orphan Biovitrum AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.69 -6.28 -0.25 -0.39 -0.18

Competitive Comparison of Swedish Orphan Biovitrum AB's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Buyback Yield % falls into.


;
;

Swedish Orphan Biovitrum AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Swedish Orphan Biovitrum AB's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 427) / 109008.8082
=-0.39%

Swedish Orphan Biovitrum AB's annualized Buyback Yield for the quarter that ended in Mar. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 178) / 98709.5418
=-0.18%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Swedish Orphan Biovitrum AB Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines